Literature DB >> 9278049

Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E.

S W Barger1, A D Harmon.   

Abstract

A role for beta-amyloid precursor protein (beta-APP) in the development of Alzheimer's disease has been indicated by genetics, and many conditions in which beta-APP is raised have been associated with an increased risk of Alzheimer's disease or an Alzheimer's-like pathology. Inflammatory events may also contribute to Alzheimer's disease. Here we investigate whether a secreted derivative of beta-APP (sAPP-alpha) can induce inflammatory reactions in microglia, which are brain cells of monocytic lineage. We found that treatment with sAPP-alpha increased markers of activation in microglia and enhanced their production of neurotoxins. The ability of sAPP-alpha to activate microglia was blocked by prior incubation of the protein with apolipoprotein E3 but not apolipoprotein E4, a variant associated with an increased risk for Alzheimer's. A product of amyloidogenic beta-APP processing (sAPP-beta) also activated microglia. Because sAPP-beta is deficient in the neuroprotective activity shown by sAPP-alpha, our results indicate that increased amyloidogenic processing could adversely affect the balance of sAPP activities that determine neuronal viability.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278049     DOI: 10.1038/42257

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  158 in total

1.  Association of microglia with amyloid plaques in brains of APP23 transgenic mice.

Authors:  M Stalder; A Phinney; A Probst; B Sommer; M Staufenbiel; M Jucker
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

Review 2.  Extracellular matrix degradation by metalloproteinases and central nervous system diseases.

Authors:  A Lukes; S Mun-Bryce; M Lukes; G A Rosenberg
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

Review 3.  The pervasiveness of interleukin-1 in alzheimer pathogenesis: a role for specific polymorphisms in disease risk.

Authors:  W S Griffin; J A Nicoll; L M Grimaldi; J G Sheng; R E Mrak
Journal:  Exp Gerontol       Date:  2000-07       Impact factor: 4.032

4.  CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.

Authors:  J Tan; T Town; T Mori; Y Wu; M Saxe; F Crawford; M Mullan
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

5.  CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.

Authors:  Yuyan Zhu; Huayan Hou; Kavon Rezai-Zadeh; Brian Giunta; Amanda Ruscin; Carmelina Gemma; Jingji Jin; Natasa Dragicevic; Patrick Bradshaw; Suhail Rasool; Charles G Glabe; Jared Ehrhart; Paula Bickford; Takashi Mori; Demian Obregon; Terrence Town; Jun Tan
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

6.  Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis.

Authors:  W Sue T Griffin; Steven W Barger
Journal:  US Neurol       Date:  2010

7.  Solution studies and structural model of the extracellular domain of the human amyloid precursor protein.

Authors:  Matthias Gralle; Michelle M Botelho; Cristiano L P de Oliveira; Iris Torriani; Sérgio T Ferreira
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

8.  Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype.

Authors:  John M Ringman; David Elashoff; Daniel H Geschwind; Brian T Welsh; Karen H Gylys; Cathy Lee; Jeffrey L Cummings; Greg M Cole
Journal:  Arch Neurol       Date:  2012-06

Review 9.  Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases.

Authors:  Tomohiro Nakamura; Dong-Hyung Cho; Stuart A Lipton
Journal:  Exp Neurol       Date:  2012-07-05       Impact factor: 5.330

Review 10.  Multitasking Microglia and Alzheimer's Disease: Diversity, Tools and Therapeutic Targets.

Authors:  Alexandra Grubman; Katja M Kanninen; Tarja Malm
Journal:  J Mol Neurosci       Date:  2016-09-22       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.